IDEAS home Printed from https://ideas.repec.org/a/plo/pmed00/1003050.html
   My bibliography  Save this article

Association between non-malignant monoclonal gammopathy and adverse outcomes in chronic kidney disease: A cohort study

Author

Listed:
  • Anthony Fenton
  • Rajkumar Chinnadurai
  • Latha Gullapudi
  • Petros Kampanis
  • Indranil Dasgupta
  • James Ritchie
  • Stephen Harding
  • Charles J Ferro
  • Philip A Kalra
  • Maarten W Taal
  • Paul Cockwell

Abstract

Background: In studies including the general population, the presence of non-malignant monoclonal gammopathy (MG) can be causally associated with kidney damage and shorter survival. We assessed whether the presence of an MG is associated with a higher risk of kidney failure or death in individuals with chronic kidney disease (CKD). Methods and findings: Data were used from 3 prospective cohorts of individuals with CKD (not on dialysis or with a kidney transplant): (1) Renal Impairment in Secondary Care (RIISC, Queen Elizabeth Hospital and Heartlands Hospital, Birmingham, UK, N = 878), (2) Salford Kidney Study (SKS, Salford Royal Hospital, Salford, UK, N = 861), and (3) Renal Risk in Derby (RRID, Derby, UK, N = 1,739). Participants were excluded if they had multiple myeloma or any other B cell lymphoproliferative disorder with end-organ damage. Median age was 71.0 years, 50.6% were male, median estimated glomerular filtration rate was 42.3 ml/min/1.73 m2, and median urine albumin-to-creatinine ratio was 3.4 mg/mmol. All non-malignant MG was identified in the baseline serum of participants of RIISC. Further, light chain MG (LC-MG) was identified and studied in participants of RIISC, SKS, and RRID. Participants were followed up for kidney failure (defined as the initiation of dialysis or kidney transplantation) and death. Associations with the risk of kidney failure were estimated by competing-risks regression (handling death as a competing risk), and associations with death were estimated by Cox proportional hazards regression. In total, 102 (11.6%) of the 878 RIISC participants had an MG. During a median follow-up time of 74.0 months, there were 327 kidney failure events and 202 deaths. The presence of MG was not associated with risk of kidney failure (univariable subhazard ratio [SHR] 0.97 [95% CI 0.68 to 1.38], P = 0.85; multivariable SHR 1.16 [95% CI 0.80 to 1.69], P = 0.43), and although there was a higher risk of death in univariable analysis (hazard ratio [HR] 2.13 [95% CI 1.49 to 3.02], P

Suggested Citation

  • Anthony Fenton & Rajkumar Chinnadurai & Latha Gullapudi & Petros Kampanis & Indranil Dasgupta & James Ritchie & Stephen Harding & Charles J Ferro & Philip A Kalra & Maarten W Taal & Paul Cockwell, 2020. "Association between non-malignant monoclonal gammopathy and adverse outcomes in chronic kidney disease: A cohort study," PLOS Medicine, Public Library of Science, vol. 17(2), pages 1-17, February.
  • Handle: RePEc:plo:pmed00:1003050
    DOI: 10.1371/journal.pmed.1003050
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003050
    Download Restriction: no

    File URL: https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1003050&type=printable
    Download Restriction: no

    File URL: https://libkey.io/10.1371/journal.pmed.1003050?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pmed00:1003050. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosmedicine (email available below). General contact details of provider: https://journals.plos.org/plosmedicine/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.